Retatrutide (often called “Reta”) is an investigational peptide developed for weight loss, obesity, and metabolic health. It is known as a triple agonist because it targets three hormone receptors at the same time: GLP-1, GIP, and glucagon receptors. This combination is designed to help reduce appetite, improve blood sugar control, increase feelings of fullness, and boost the body’s calorie-burning ability.
Potential benefits being studied include:
- Significant weight loss
- Reduced appetite and food cravings
- Improved insulin sensitivity
- Better blood sugar regulation
- Increased fat oxidation and energy expenditure
- Possible improvements in metabolic health and fatty liver disease
Commonly reported side effects may include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Fatigue
- Stomach discomfort
- Temporary increases in heart rate
Retatrutide has shown impressive weight-loss results in clinical trials, but it is still under investigation and is not currently FDA-approved. Researchers continue studying its long-term safety and effectiveness.
vial arrives in crystal form.
for research purposes only.